Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Lucid-21-302
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Ingenu CRO
Deal Size : Undisclosed
Deal Type : Agreement
Quantum Biopharma Partners with Ingenu CRO For Multiple Sclerosis Study
Details : Ingenu will conduct a clinical study to observe and quantify disease progression in patients with primary progressive multiple sclerosis facilitating a future phase 2 with Lucid-21-302 (Lucid-MS).
Brand Name : Lucid-MS
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 09, 2024
Lead Product(s) : Lucid-21-302
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Ingenu CRO
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?